You can buy or sell BPTH and other stocks, options, ETFs, and crypto commission-free!
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. Read More The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.
52 Week High
52 Week Low
Bio-Path Holdings (BPTH) CEO, Peter Nielsen on Q 2018 Results - Earnings Call Transcript
Bio-Path Holdings (NASDAQ:BPTH) Q4 2018 Earnings Conference Call March 20, 2019 8:30 AM ET Company Participants Peter Nielsen - President, Chief Executive Officer Anthony Price - Vice President, Finance and Accounting Will O’Connor - Stern Investor Relations Conference Call Participants Laura Engle - Stonegate Capital Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings full year 2018 earnings conference call. At this time, all participants are in a listen-only mode. Followin...
Bio-Path Holdings Reports Full Year 2018 Financial Results
HOUSTON, March 20, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the full year ended December 31, 2018 and provided an update on recent corporate developments. “Throughout 2018, we made great progress in pursuit of our mission of bringing innovative new RNAi nanoparticle therapeutics to...
AbbVie Inc. Stock Quote (U.S.: NYSE)
Shares of Bio-Path Holdings Inc. shot up another 130% on Thursday morning, one day after the company announced an update to its Phase 2 trial data on prexigebersen, a potential therapy for patients with acute myeloid leukemia (AML). The tiny biotech was the most heavily traded stock on the Nasdaq on Wednesday afternoon, with shares rocketing 160%. The trial enrolled 17 patients and looked at the safety and efficacy of prexigebersen combined with low-dose cytarabine compared with just low-dose cytarabine alo...
Available Mar 19, After Hours